Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis (PN)

NCT03181503 is registered in ClinicalTrials.gov with Galderma R&D as lead sponsor.

NCT NCT03181503
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03181503 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis (PN)
Lead sponsor
Galderma R&D
Phase
Phase 2
Overall status
Completed
Start date
October 2, 2017
Completion date
September 26, 2018
Enrollment
70 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

prurigo nodularis